Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895090 | 1.00 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3NOS1GRIN2D | |
| SCHEMBL2895084 | 1.00 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3NOS1GRIN2D | |
| Ip-2018 SCHEMBL25368803 | 0.78 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3 | |
| Ip-2018 SCHEMBL26041644 | 0.78 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3 | |
| Ip-2018 SCHEMBL1103728 | 0.78 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL19139451 | 0.78 | NOS1 (0.46) | NOS1GRIN2DGRIN3BGRIN1GRIN2A | |
| Ip-2018 SCHEMBL31440785 | 0.77 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| Ip-2018 SCHEMBL2191263 | 0.77 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2896498 | 0.76 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2896496 | 0.76 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286195-A1 | NOVEL BENZOOXAZOL-AND BENZOOXATHIOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-11-11 | — | — | US | claimed |
| EP-2201004-A1 | NOVEL BENZOOXAZOL- AND BENZOOXATHIOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-06-30 | — | — | EP | claimed |
| WO-2009034042-A1 | NOVEL BENZOOXAZOL- AND BENZOOXATHIOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-03-19 | — | — | WO | claimed |
| US-20100286195-A1 | NOVEL BENZOOXAZOL-AND BENZOOXATHIOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-11-11 | — | — | US | disclosed |
| EP-2201004-A1 | NOVEL BENZOOXAZOL- AND BENZOOXATHIOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009034042-A1 | NOVEL BENZOOXAZOL- AND BENZOOXATHIOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286195-A1 | NOVEL BENZOOXAZOL-AND BENZOOXATHIOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, MAOB, SLC6A2 | SLC6A4 11/4885SLC6A2 3/4885SLC6A3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.